NCT01203930 - A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2015

Study Completion Date

June 30, 2016

Conditions

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG

Idelalisib

Idelalisib 150 mg tablets administered orally twice daily

DRUG

Rituximab

Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks

Trial Locations (6)

Columbia University - Herbert Irving Pavilion, New York

Memorial Sloan Kettering Cancer Center, New York

Sarah Cannon Research Institute, Nashville

The Universtity of Texas MD Anderson Cancer Center, Houston

Stanford University School of Medicine, Stanford

University of California, San Diego, Moores Cancer Center, La Jolla